-+ 0.00%
-+ 0.00%
-+ 0.00%

ST Renfu (600079.SH): HW281171 tablets obtained approval notice for drug clinical trials

Zhitongcaijing·11/10/2026 08:25:10
Listen to the news

Zhitong Finance App News, ST Renfu (600079.SH) issued an announcement. Hubei Biomedical Industry Technology Research Institute Co., Ltd. (“Research Institute Co., Ltd.”), a wholly-owned subsidiary of the company, recently received the HW281171 “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration.

HW281171 tablets are intended for the treatment of chronic urticaria and are a new small-molecule drug for oral administration. Up to now, the project has invested around RMB 30 million in R&D. Urticaria is a limited edematous reaction caused by dilation of small blood vessels in the skin and mucous membranes and increased permeability. The course of the disease is repeated and the burden of disease is heavy, and intractable severe itching seriously interferes with the patient's sleep quality and mental health.